ARTICLE | Clinical News
VXM01: Phase I data
June 27, 2016 7:00 AM UTC
Data from 16 evaluable patients with advanced pancreatic cancer in a dose-escalation, placebo-controlled Phase I trial showed that low- and high-dose VXM01 led to increases in vaccine-specific T cell ...